Equities analysts predict that Calithera Biosciences, Inc. (NASDAQ:CALA) will announce earnings per share of ($0.24) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Calithera Biosciences’ earnings, with the highest EPS estimate coming in at ($0.19) and the lowest estimate coming in at ($0.29). Calithera Biosciences posted earnings per share of ($0.45) in the same quarter last year, which indicates a positive year-over-year growth rate of 46.7%. The business is expected to announce its next earnings results on Thursday, March 15th.

According to Zacks, analysts expect that Calithera Biosciences will report full year earnings of ($0.77) per share for the current fiscal year, with EPS estimates ranging from ($0.83) to ($0.73). For the next financial year, analysts anticipate that the company will post earnings of ($0.80) per share, with EPS estimates ranging from ($0.98) to ($0.45). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that that provide coverage for Calithera Biosciences.

Calithera Biosciences (NASDAQ:CALA) last announced its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.06. The firm had revenue of $7.20 million during the quarter, compared to analysts’ expectations of $6.02 million.

A number of brokerages recently issued reports on CALA. William Blair began coverage on shares of Calithera Biosciences in a research report on Thursday, October 5th. They set an “outperform” rating for the company. BidaskClub raised shares of Calithera Biosciences from a “strong sell” rating to a “sell” rating in a research report on Friday, August 18th. Finally, Zacks Investment Research cut shares of Calithera Biosciences from a “buy” rating to a “hold” rating in a research report on Thursday, July 13th. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $15.50.

In other Calithera Biosciences news, major shareholder Adage Capital Partners Gp, L.L sold 576,000 shares of the firm’s stock in a transaction dated Thursday, September 28th. The shares were sold at an average price of $15.64, for a total transaction of $9,008,640.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 16.30% of the stock is currently owned by company insiders.

Several hedge funds have recently made changes to their positions in the company. FMR LLC grew its stake in shares of Calithera Biosciences by 85.8% in the second quarter. FMR LLC now owns 2,717,090 shares of the biotechnology company’s stock worth $40,349,000 after acquiring an additional 1,254,900 shares during the period. State Street Corp grew its stake in shares of Calithera Biosciences by 5,802.1% in the second quarter. State Street Corp now owns 1,304,375 shares of the biotechnology company’s stock worth $19,370,000 after acquiring an additional 1,282,275 shares during the period. Vanguard Group Inc. grew its stake in shares of Calithera Biosciences by 29.7% in the second quarter. Vanguard Group Inc. now owns 1,199,525 shares of the biotechnology company’s stock worth $17,813,000 after acquiring an additional 274,510 shares during the period. Lord Abbett & CO. LLC grew its stake in shares of Calithera Biosciences by 65.5% in the second quarter. Lord Abbett & CO. LLC now owns 497,811 shares of the biotechnology company’s stock worth $7,392,000 after acquiring an additional 197,055 shares during the period. Finally, American Century Companies Inc. grew its stake in shares of Calithera Biosciences by 272.8% in the third quarter. American Century Companies Inc. now owns 424,752 shares of the biotechnology company’s stock worth $6,690,000 after acquiring an additional 310,806 shares during the period. Hedge funds and other institutional investors own 71.22% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This article was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.watchlistnews.com/brokerages-expect-calithera-biosciences-inc-cala-will-announce-earnings-of-0-24-per-share/1683525.html.

Calithera Biosciences (NASDAQ CALA) traded down $0.30 during midday trading on Monday, hitting $16.90. The stock had a trading volume of 343,929 shares, compared to its average volume of 445,448. Calithera Biosciences has a fifty-two week low of $2.50 and a fifty-two week high of $20.05.

About Calithera Biosciences

Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

Get a free copy of the Zacks research report on Calithera Biosciences (CALA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Calithera Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.